Recent studies have evaluated the effectiveness of blood-based phosphorylated tau (p-tau) biomarkers in diagnosing AD (Table 2), comparing their performance to traditional cerebrospinal fluid (CSF) analyses and positron emission tomography (PET) imaging. The gene discussed is MAPT; the disease is Alzheimer disease.